# Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial

> **NCT02319187** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 240 (estimated)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **DRUG:** S1
- **DRUG:** S-1
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT02319187
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-06
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2015-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319187, "Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02319187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*